GlycoMimetics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

CRESCENT BIOPHARMA, INC.

Received Nasdaq notice on June 21, 2024 for bid price below $1.00 for 30 consecutive business days.
Has until December 18, 2024 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
Failure to regain compliance could result in delisting of GLYC common stock from Nasdaq.
Company intends to monitor bid price and consider options; no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.